Results 171 to 180 of about 9,532 (200)

[Process in development of PTH, an awaited bone-density conservation agent].

, 2012
Toshitsugu Sugimoto
openalex  

[New bone density conservation agents for osteoporosis under research and development: PTH (1-34)].

, 2007
Itsuro Endo, Toshio Matsumoto
openalex  

Some of the next articles are maybe not open access.

Related searches:

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Hope S Rugo
exaly  

[New bone density conservation agents for osteoporosis under research and development: Strontium ranelate].

, 2007
Masataka Shiraki
openalex  

[New bone density conservation agents for osteoporosis under research and development: Zoledronate].

, 2007
Seiki Wada, Takeshi Fukawa, Sadahiro Kamiya   +2 more
openalex  

Epithelial ovarian cancer: Evolution of management in the era of precision medicine

Ca-A Cancer Journal for Clinicians, 2019
Stephanie Lheureux, Marsela Braunstein, Amit M Oza   +2 more
exaly  

[New bone density conservation agents for osteoporosis under research and development: PTH (1-34)].

Nihon rinsho. Japanese journal of clinical medicine, 2008
Itsuro, Endo, Toshio, Matsumoto
openaire   +1 more source

[New bone density conservation agents for osteoporosis under research and development: Minodronic acid].

, 2007
Shinjiro Takata
openalex  

[New bone density conservation agents for osteoporosis under research and development: Anti-RANKL antibody].

Nihon rinsho. Japanese journal of clinical medicine, 2008
Seiki, Wada, Takeshi, Fukawa, Sadahiro, Kamiya   +2 more
openaire   +1 more source

[New bone density conservation agents for osteoporosis under research and development: Anti-RANKL antibody].

, 2007
Seiki Wada, Takeshi Fukawa, Sadahiro Kamiya   +2 more
openalex